{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:54:39Z","timestamp":1794275679450,"version":"4.9.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018787","name":"Novartis Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["worldallergyorganizationjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Allergy Organization Journal"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.waojou.2023.100788","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T22:32:20Z","timestamp":1686868340000},"page":"100788","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Vernal keratoconjunctivitis: Current immunological and clinical evidence and the potential role of omalizumab"],"prefix":"10.1016","volume":"16","author":[{"given":"Serge","family":"Doan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos G.","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Manti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Rondon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Pleyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Jaumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slawomir B.","family":"Lazarewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.waojou.2023.100788_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/iid3.384","article-title":"Clinical efficacy and safety of omalizumab in conventional treatment-resistant vernal keratoconjunctivitis: our experience and literature review","volume":"9","author":"Manti","year":"2021","journal-title":"Immun Inflamm Dis"},{"issue":"6","key":"10.1016\/j.waojou.2023.100788_bib2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40629-020-00128-4","article-title":"Omalizumab in three children with severe vernal keratoconjunctivitis","volume":"29","author":"Rossberg","year":"2020","journal-title":"Allergo J Int"},{"issue":"5","key":"10.1016\/j.waojou.2023.100788_bib3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.aller.2011.08.002","article-title":"Omalizumab. An option in vernal keratoconjunctivitis?","volume":"40","author":"Sanchez","year":"2012","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"8","key":"10.1016\/j.waojou.2023.100788_bib4","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1136\/bjo.2007.117812","article-title":"Prevalence of vernal keratoconjunctivitis: a rare disease?","volume":"92","author":"Bremond-Gignac","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"10.1016\/j.waojou.2023.100788_bib5","first-page":"4592","article-title":"Epidemiology of vernal\u00a0keratoconjunctivitis in the United States: a claims data\u00a0analysis","volume":"61","author":"Babineaux","year":"2020","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.waojou.2023.100788_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215528","article-title":"Prevalence of vernal keratoconjunctivitis and its associated factors among children in Gambella town, southwest Ethiopia, June 2018","volume":"14","author":"Alemayehu","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.waojou.2023.100788_bib7","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13052-019-0656-4","article-title":"Vernal Keratoconjunctivitis: an update focused on clinical grading system","volume":"45","author":"Zicari","year":"2019","journal-title":"Ital J Pediatr"},{"issue":"6","key":"10.1016\/j.waojou.2023.100788_bib8","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0161-6420(00)00092-0","article-title":"Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup","volume":"107","author":"Bonini","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.waojou.2023.100788_bib9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2147\/OPTH.S129552","article-title":"Vernal keratoconjunctivitis","volume":"12","author":"Addis","year":"2018","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"10.1016\/j.waojou.2023.100788_bib10","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1177\/11206721211022153","article-title":"Vernal keratoconjunctivitis: an update","volume":"31","author":"Ghiglioni","year":"2021","journal-title":"Eur J Ophthalmol"},{"issue":"5","key":"10.1016\/j.waojou.2023.100788_bib11","first-page":"e36","article-title":"Vernal keratoconjunctivitis: beyond the classic treatment","volume":"58","author":"Bernales","year":"2021","journal-title":"J\u00a0Pediatr Ophthalmol Strabismus"},{"issue":"S7","key":"10.1016\/j.waojou.2023.100788_bib12","article-title":"Vernal keratoconjunctivitis: state of art and update on treatment","volume":"92","author":"Brindisi","year":"2021","journal-title":"Acta Biomed"},{"issue":"10","key":"10.1016\/j.waojou.2023.100788_bib13","first-page":"1012","article-title":"Understanding vernal keratoconjunctivitis: beyond allergic mechanisms","volume":"11","author":"Sacchetti","year":"2021","journal-title":"Life (Basel)"},{"issue":"7","key":"10.1016\/j.waojou.2023.100788_bib14","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3390\/ph14070658","article-title":"Immunopharmacology in vernal keratoconjunctivitis: current and future perspectives","volume":"14","author":"Chigbu","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"10.1016\/j.waojou.2023.100788_bib15","first-page":"CD013298","article-title":"Systemic interventions for severe atopic and vernal keratoconjunctivitis in children and young people up to the age of 16 years","author":"Kim","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.waojou.2023.100788_bib16","doi-asserted-by":"crossref","first-page":"108","DOI":"10.5415\/apallergy.2011.1.3.108","article-title":"Ocular allergy in the Asia pacific region","volume":"1","author":"Katelaris","year":"2011","journal-title":"Asia Pac Allergy"},{"key":"10.1016\/j.waojou.2023.100788_bib17","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jtos.2021.05.003","article-title":"Ocular redness - I: etiology, pathogenesis, and assessment of conjunctival hyperemia","volume":"21","author":"Singh","year":"2021","journal-title":"Ocul Surf"},{"issue":"9","key":"10.1016\/j.waojou.2023.100788_bib18","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1111\/all.13786","article-title":"Management of ocular allergy","volume":"74","author":"Leonardi","year":"2019","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.waojou.2023.100788_bib19","first-page":"19","article-title":"The clinical significance of perilimbal conjunctival pigmentation in vernal conjunctivitis","volume":"22","author":"Khan","year":"2012","journal-title":"J Coll Physicians Surg Pak"},{"issue":"5","key":"10.1016\/j.waojou.2023.100788_bib20","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/ACI.0000000000000202","article-title":"Corneal complications of vernal keratoconjunctivitis","volume":"15","author":"Solomon","year":"2015","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.waojou.2023.100788_bib21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5409\/wjcp.v10.i4.48","article-title":"Can omalizumab be used effectively to treat severe conjunctivitis in children with asthma? A case example and review of the literature","volume":"10","author":"Doherty","year":"2021","journal-title":"World J Clin Pediatr"},{"issue":"230","key":"10.1016\/j.waojou.2023.100788_bib22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1034\/j.1600-0420.2000.078s230018.x","article-title":"Role of histamine in allergic conjunctivitis","author":"Leonardi","year":"2000","journal-title":"Acta Ophthalmol Scand Suppl"},{"issue":"5","key":"10.1016\/j.waojou.2023.100788_bib23","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.jaip.2019.02.030","article-title":"IgE-mediated multimorbidities in allergic asthma and the potential for omalizumab therapy","volume":"7","author":"Humbert","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"10","key":"10.1016\/j.waojou.2023.100788_bib24","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.4103\/ijo.IJO_1191_19","article-title":"Relevance of IgE, allergy and eye rubbing in the pathogenesis and management of Keratoconus","volume":"68","author":"Ahuja","year":"2020","journal-title":"Indian J Ophthalmol"},{"issue":"2","key":"10.1016\/j.waojou.2023.100788_bib25","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/0091-6749(80)90057-3","article-title":"Specific immunoglobulin E antibodies in tear secretions of patients with vernal conjunctivitis","volume":"66","author":"Ballow","year":"1980","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.waojou.2023.100788_bib26","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/pai.12450","article-title":"Microarray-based IgE detection in tears of patients with vernal keratoconjunctivitis","volume":"26","author":"Leonardi","year":"2015","journal-title":"Pediatr Allergy Immunol"},{"issue":"26","key":"10.1016\/j.waojou.2023.100788_bib27","first-page":"104","article-title":"Tearfilm\u00a0immunoglobulin E (IgE) level in vernal keratoconjunctivitis by\u00a0ELISA","volume":"7","author":"Pokharel","year":"2009","journal-title":"Kathmandu Univ Med J (KUMJ)"},{"issue":"8","key":"10.1016\/j.waojou.2023.100788_bib28","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3390\/biom11081084","article-title":"Pathological roles and clinical usefulness of periostin in type 2 inflammation and pulmonary fibrosis","volume":"11","author":"Ono","year":"2021","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.waojou.2023.100788_bib29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/aos.15212","article-title":"Prevalence of allergic sensitization with vernal keratoconjunctivitis: a systematic review with meta-analyses","volume":"101","author":"Rasmussen","year":"2023","journal-title":"Acta Ophthalmologica"},{"issue":"2","key":"10.1016\/j.waojou.2023.100788_bib30","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/eye.1998.68","article-title":"Tear IgE concentrations in allergic conjunctivitis","volume":"12","author":"Nomura","year":"1998","journal-title":"Eye"},{"issue":"4","key":"10.1016\/j.waojou.2023.100788_bib31","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2332\/allergolint.09-OA-0101","article-title":"Clinical evaluation of total IgE in tears of patients with allergic conjunctivitis disease using a novel application of the\u00a0immunochromatography method","volume":"58","author":"Inada","year":"2009","journal-title":"Allergol Int"},{"issue":"1","key":"10.1016\/j.waojou.2023.100788_bib32","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40123-016-0074-2","article-title":"Omalizumab in severe refractory vernal keratoconjunctivitis in children: case series and review of the literature","volume":"6","author":"Doan","year":"2017","journal-title":"Ophthalmol Ther"},{"issue":"5","key":"10.1016\/j.waojou.2023.100788_bib33","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/ACI.0b013e3282ef8674","article-title":"Immunopathogenesis\u00a0of ocular allergy: a schematic approach to different clinical\u00a0entities","volume":"7","author":"Leonardi","year":"2007","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.waojou.2023.100788_bib34","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.anai.2020.11.016","article-title":"The spectrum of allergic ocular diseases","volume":"126","author":"Rodrigues","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"9","key":"10.1016\/j.waojou.2023.100788_bib35","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/j.ophtha.2005.04.009","article-title":"Expression of toll-like receptors in healthy and allergic conjunctiva","volume":"112","author":"Bonini","year":"2005","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.waojou.2023.100788_bib36","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/02713683.2016.1242755","article-title":"Clinical usefulness of simultaneous measurement of the tear levels of CCL17, CCL24, and IL-16 for the biomarkers of allergic conjunctival disorders","volume":"42","author":"Shoji","year":"2017","journal-title":"Curr Eye Res"},{"issue":"12","key":"10.1016\/j.waojou.2023.100788_bib37","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1517\/14712598.5.12.1603","article-title":"Omalizumab: a future innovation for treatment of severe ocular allergy?","volume":"5","author":"Williams","year":"2005","journal-title":"Expet Opin Biol Ther"},{"key":"10.1016\/j.waojou.2023.100788_bib38","series-title":"Xolair (Omalizumab) Injection","year":"2021"},{"issue":"1","key":"10.1016\/j.waojou.2023.100788_bib39","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000350486","article-title":"Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial","volume":"162","author":"Iyengar","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.waojou.2023.100788_bib40","doi-asserted-by":"crossref","DOI":"10.1177\/2058738420942386","article-title":"Evolution of our view on the IgE molecule role in bronchial asthma and the clinical effect of its modulation by omalizumab: where do we stand today?","volume":"34","author":"Novosad","year":"2020","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"12","key":"10.1016\/j.waojou.2023.100788_bib41","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1111\/j.1398-9995.2009.02201.x","article-title":"Effects of omalizumab on markers of inflammation in patients with allergic asthma","volume":"64","author":"Holgate","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.waojou.2023.100788_bib42","unstructured":"Xolair 150 mg solution for injection in pre-filled syringe. Summary of product characteristics. Updated 15 February 2022. https:\/\/www.medicines.org.uk\/emc\/product\/4725\/smpc#gref [accessed 7 August 2022]."},{"key":"10.1016\/j.waojou.2023.100788_bib43","series-title":"Xolair (Omalizumab). Data on File. Safety Update","year":"2018"},{"issue":"3","key":"10.1016\/j.waojou.2023.100788_bib44","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1183\/09031936.04.00024504","article-title":"Omalizumab inhibits allergen challenge-induced nasal response","volume":"23","author":"Hanf","year":"2004","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.waojou.2023.100788_bib45","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jaci.2006.02.028","article-title":"Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma","volume":"117","author":"Noga","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.waojou.2023.100788_bib46","first-page":"232","article-title":"The effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma","volume":"84","author":"Kuprys-Lipinska","year":"2016","journal-title":"Pneumonol Alergol Pol"},{"key":"10.1016\/j.waojou.2023.100788_bib47","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/3254094","article-title":"Omalizumab for severe asthma: beyond allergic asthma","volume":"2018","author":"Loureiro","year":"2018","journal-title":"BioMed Res Int"},{"issue":"4","key":"10.1016\/j.waojou.2023.100788_bib48","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.ejcdt.2015.07.002","article-title":"Study of the effect of anti-IgE (omalizumab) on serum level of matrix metalloproteinase-9 as a marker of remodeling in severe asthmatic patients","volume":"64","author":"Affara","year":"2015","journal-title":"Egypt J Chest Dis Tuberc"},{"issue":"9","key":"10.1016\/j.waojou.2023.100788_bib49","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/resp.14096","article-title":"Anti-IgE therapy inhibits chemotaxis, proliferation and transformation of circulating fibrocytes in patients with severe allergic asthma","volume":"26","author":"Wang","year":"2021","journal-title":"Respirology"},{"issue":"11","key":"10.1016\/j.waojou.2023.100788_bib50","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1111\/all.15449","article-title":"Regulatory T cells and immunoglobulin E: a new therapeutic link for autoimmunity?","volume":"77","author":"Palomares","year":"2022","journal-title":"Allergy"},{"issue":"8","key":"10.1016\/j.waojou.2023.100788_bib51","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1164\/rccm.201701-0120OC","article-title":"Effects of omalizumab on rhinovirus infections, illnesses, and exacerbations of asthma","volume":"196","author":"Esquivel","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.waojou.2023.100788_bib52","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13223-020-0403-9","article-title":"A contemporary look at allergic conjunctivitis","volume":"16","author":"Dupuis","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"1","key":"10.1016\/j.waojou.2023.100788_bib53","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4274\/tjo.galenos.2020.11456","article-title":"Current knowledge in allergic conjunctivitis","volume":"51","author":"Villegas","year":"2021","journal-title":"Turk J Ophthalmol"},{"issue":"4","key":"10.1016\/j.waojou.2023.100788_bib54","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaophthalmol.2015.5679","article-title":"Omalizumab treatment of vernal keratoconjunctivitis","volume":"134","author":"Heffler","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.waojou.2023.100788_bib55","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.aller.2017.12.002","article-title":"Quality of life and clinical characterization of patients with vernal keratoconjunctivitis in a pediatric population\u00a0in Colombia","volume":"46","author":"Gomez-Henao","year":"2018","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"3","key":"10.1016\/j.waojou.2023.100788_bib56","first-page":"305","article-title":"Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab","volume":"17","author":"de Klerk","year":"2013","journal-title":"J\u00a0AAPOS"},{"issue":"Suppl 106","key":"10.1016\/j.waojou.2023.100788_bib57","first-page":"3","article-title":"Abstract OA0027 from the European Academy of Allergy and Clinical Immunology congress, 01-05 June 2019, Lisbon, Portugal","volume":"74","year":"2019","journal-title":"Allergy"},{"issue":"Suppl 102","key":"10.1016\/j.waojou.2023.100788_bib58","first-page":"118","volume":"71","year":"2016","journal-title":"Abstract 253 from the European Academy of Allergy and Clinical Immunology congress, 11-15 June 2016, Vienna, Austria. Allergy"},{"issue":"5","key":"10.1016\/j.waojou.2023.100788_bib59","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/pai.12737","article-title":"Vernal keratoconjunctivitis treated with omalizumab: a case series","volume":"28","author":"Occasi","year":"2017","journal-title":"Pediatr Allergy Immunol"},{"issue":"2","key":"10.1016\/j.waojou.2023.100788_bib60","doi-asserted-by":"crossref","first-page":"AB174","DOI":"10.1016\/j.jaci.2018.12.534","article-title":"Vernal keratoconjunctivitis treated with omalizumab: a series of cases","volume":"143","author":"Silva","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.waojou.2023.100788_bib61","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/ced.15000","article-title":"Successful treatment of severe recalcitrant vernal keratoconjunctivitis and atopic dermatitis associated with elevated IgE levels with omalizumab","volume":"47","author":"Zengarini","year":"2022","journal-title":"Clin Exp Dermatol"},{"issue":"Suppl 24","key":"10.1016\/j.waojou.2023.100788_bib62","first-page":"65","article-title":"Papale M. et al. Effectiveness of omalizumab in two children with severe vernal keratoconjunctivitis","volume":"31","author":"Tardino","year":"2020","journal-title":"Pediatr Allergy Immunol"},{"issue":"S109","key":"10.1016\/j.waojou.2023.100788_bib63","first-page":"307","article-title":"Abstract 1429 from the European Academy of Allergy and Clinical Immunology digital congress, 06-08 June 2020","volume":"75","year":"2020","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.waojou.2023.100788_bib64","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.anai.2018.09.458","article-title":"Omalizumab as single-dose therapy for vernal keratoconjunctivitis","volume":"122","author":"Simpson","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.waojou.2023.100788_bib65","doi-asserted-by":"crossref","first-page":"192","DOI":"10.29262\/ram.v65i2.292","article-title":"Sanchez J. Eficacia a largo plazo del omalizumab en pacientes con queratoconjuntivitis vernal resistente a tratamiento convencional","volume":"65","author":"Santamaria","year":"2018","journal-title":"Rev Alerg Mex"},{"issue":"Suppl 102","key":"10.1016\/j.waojou.2023.100788_bib66","first-page":"118","article-title":"Abstract 259 from the European Academy of Allergy and Clinical Immunology congress, 11-15 June 2016, Vienna, Austria","volume":"71","year":"2016","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.waojou.2023.100788_bib67","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/pai.12350","article-title":"Vernal keratoconjunctivitis and immune-mediated diseases: one unique way to symptom control?","volume":"26","author":"Occasi","year":"2015","journal-title":"Pediatr Allergy Immunol"}],"container-title":["World Allergy Organization Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455123000480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1939455123000480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:46:11Z","timestamp":1761849971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1939455123000480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1939455123000480"],"URL":"https:\/\/doi.org\/10.1016\/j.waojou.2023.100788","relation":{},"ISSN":["1939-4551"],"issn-type":[{"value":"1939-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vernal keratoconjunctivitis: Current immunological and clinical evidence and the potential role of omalizumab","name":"articletitle","label":"Article Title"},{"value":"World Allergy Organization Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.waojou.2023.100788","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of World Allergy Organization.","name":"copyright","label":"Copyright"}],"article-number":"100788"}}